Sandoz Opens Two European Sites, In Biosimilars And Antibiotics
Announcement Comes As Company Raises €2.0bn In Debt Following Spin
Executive Summary
Newly separated Sandoz has provided a trio of updates, foremost for its manufacturing and research ambitions for both biosimilars and antibiotics.